Company Description
Carlsmed is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).
The aprevo Technology Platform was designed to address the limitations of traditional spine fusion surgery and aims to optimize patient outcomes and reduce the need for revision surgeries.
By providing personalized surgical plans and interbody implants for custom vertebral fit that are powered by AI-enabled, outcomes-based algorithms, the aprevo Technology Platform supports surgeons in achieving proper spinal alignment for patients with degenerative disc disease, which can improve clinical outcomes and reduce the likelihood of revision surgeries.
We currently market the aprevo Technology Platform for lumbar spine fusion surgery, and we are further developing the aprevo Technology Platform for use in cervical spine fusion surgeries, which we expect to commercialize in 2026.
Country | United States |
Founded | 2018 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 100 |
CEO | Michael Cordonnier |
Contact Details
Address: 1800 Aston Ave, Suite 100 Carlsbad, CA 92008 United States | |
Phone | (760) 766-1923 |
Website | carlsmed.com |
Stock Details
Ticker Symbol | CARL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001794546 |
Employer ID | 83-1081863 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Michael (Mike) Cordonnier | Chairman, Chief Executive Officer, President, and Co-Founder |
Leonard (Leo) Greenstein | Chief Financial Officer, Treasurer |
William (Scott) Durall | Chief Commercial Officer |
Niall Casey | Co-Founder, Chief Intellectual Property Officer, Secretary, Director |
Jonathan (Jon) Root, M.D. | Director |
Robert Mittendorff, M.D. | Director |
Philip (Phil) Young | Director |
Kevin Sidow | Director |
Kevin O’Boyle | Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 26, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
May 30, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
Apr 24, 2025 | DRS | [Cover] Draft Registration Statement |
Feb 7, 2025 | D/A | Filing |
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Apr 27, 2022 | D | Notice of Exempt Offering of Securities |
Dec 17, 2020 | D | Notice of Exempt Offering of Securities |
May 15, 2020 | D/A | Filing |
Nov 19, 2019 | D | Notice of Exempt Offering of Securities |